Russian Call Girls in Pune Riya 9907093804 Short 1500 Night 6000 Best call gi...
Percutaneous left atrial appendage
1. Left atrial appendage occlusion for
stroke prevention in atrial fibrillation
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
2. INTRODUCTION
AF
0.4% to 1% of the general population.
most common sustained cardiac arrhythmia
3–5% of the population aged 65–75 years
increasing to >8% of those older than 80 years.
risk of ischaemic stroke in non-valvular
AF(NVAF) is 3–5%/year, which is a fivefold
increase compared with the unaffected population
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
3. AF
• 15–20% of strokes in the general population and
for up to 30% in patients over the age of 80
years.
• prevention of stroke-OAC is the standard
treatment in patients with AF with a
CHA(2)DS2-(VASc) stroke risk score ≥1.
• LAA occlusion -AF with a high stroke risk and
contraindications for OAC.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
5. Rationale for LAA occlusion
60% of atrial thrombi in valvular AF – LAA
in NVAF >90% of thrombi were located in the
LAA.
LAA found to be the dominant source of
thrombus in patients with NVAF
reduces the risk of AF-induced stroke in such a
range that it outweighs the possible risk on
procedural complications.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
6. INDICATION
ESC (2012) -LAA closure may be considered in
patients with a high stroke risk and
contraindications for long-term OAC
administration
(Class IIb, level of evidence B)
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
7. Patient selection
All patients with NVAF with increased stroke risk
and contraindication(s) to OAC
Patients with NVAF with a high stroke (CHADS2)
and bleeding (HAS-BLED) risk score
Higher the stroke risk of the individual patient,
the larger the ‘Net clinical benefit’ of LAA closure
in comparison to OAC therapy
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
8. Patients with a high risk for thromboembolism—
for example, left ventricular (LV) dysfunction or
prior stroke—have also been reported to be at a
higher risk of thrombus formation in the LA cavity
(and not in the LAA) and device thrombosis.
combined risk of stroke, thromboembolism,
bleeding and other adverse events - best way to
select patients most suitable for LAA closure.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
9. Indications for percutaneous LAA
closure
Patients with AF at high stroke risk with high risk
(or recurrence) of bleeding under (N)OAC due to
Uncontrolled, severe hypertension
Coagulopathies—low platelet counts, MDS
Inherited bleeding disorder— vWD,
haemophilia
Severe hepatic or renal dysfunction—eg,
alcoholic liver disease,cirrhosis
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
10. Vascular disease or malformations— eg,
intestinal angiodysplasia,Osler-Weber-Rendu
disease,previous intracerebral
haemorrhage,cerebral microbleeds (∼amyloid
angiopathy), retinal vasculopathy
Insufficiently treatable GI disease with bleeding—
eg, neoplastic disease, intestinal angiodysplasia
Recurrent nephrolithiasis
High probability of frequent and/or severe
traumas—eg, epilepsy,in the elderly
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
11. Ischaemic stroke despite well controlled OAC
therapy
High probability of therapeutic non-compliance to
(N)OAC
Intolerance to (N)OAC drugs--GI intolerance,
severe liver/
kidney dysfunction, drug interactions
Other contraindications for (N)OAC
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
12. Contraindications for percutaneous
LAA closure
Low risk for stroke CHA(2)DS2-(VASc)=0
VHD(eg, MS)
Other indications for long-term or lifelong
OAC—mechanical prosthetic valve, PTE and
DVT ,thrombi in the LA or LV
Contraindications for transseptal LA thrombus
or tumour, active infection, uncooperative
patient,( presence of ASD/PFO closure
device) a thrombus in the LAA
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
13. LAA anatomy
• The LAA derives from the primordial left atrium
(LA), which is formed mainly by the adsorption of
the primordial
pulmonary veins and their branches.
• LAA has a highly variable anatomical structure ,it
is important to correctly evaluate the LAA
anatomy
• best way -MDCT and/or angiography
• LAA orifice and neck can also readily be
examined by TEE
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
14. LAA extends between the anterior and the lateral
walls of the LA, and its tip is directed
anterosuperiorly, overlapping
the left border of RVOT or PT and the main stem
of LM or LCX.
Veinot et al. defined lobes as protrusions from
the main body with the tail portion also
representing a lobe, whereas bends in the tail do
not constitute more lobes.
2 lobes were most common(54%), followed by 3
lobes (23%), 1 lobe (20%), and 4 lobes (3%),
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
15. An increased number of lobes was associated
with the presence of a thrombus
muscle bundles in the LAA do not ramify like the
teeth of a comb but instead, they have a feather-
type-palm-leaf arrangement.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
16. LAA classification
(1) chicken wing: an LAA with an obvious bend in
the proximal part of the dominant lobe;
(2) windsock: an LAA with a main lobe of
sufficient length (>4 cm) as the primary structure;
(3) cauliflower: an LAA that has limited overall
length (<4 cm) without any forked lobes;
(4) cactus: a dominant central lobe with
secondary lobes extending from the central lobe.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
19. ‘chicken wing’ -lower stroke risk , procedural
challenge and a modified implantation technique
may be preferred.
‘cauliflower’ morphology /smaller LAA orifice,
larger neck dimension and extensive LAA
trabeculation -higher stroke risk
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
20. understanding the different configurations of the
LAA ostium and neck is vital, as the occluder is
anchored at the neck and must cover the ostium.
Three different morphologies of the LAA ostium
and neck: (1) Horn shaped: LAA ostium wider
than the neck,
(2) Parallel tube: an ostium and neck that are
similar in dimension and
(3) Angel wing: a neck with larger dimensions
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
21. LAA FUNCTION AND THROMBUS
FORMATION
Normal contraction of the LAA during SR and
adequate blood flow within the LAA lower the risk
for thrombi
Thrombus formation - reduced contractility and
stasis ensue.
AF -decrease in LAA contractility and function,
manifest as a decrease in Doppler velocities and
dilation of the LAA.
Significant LV dysfunction and elevated LV EDP
-LAA thrombus formation in the absence of AF.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
22. NONINVASIVE IMAGING OF THE
LAA
FOR RISK ASSESSMENT
TEE - LAA morphology and flow patterns within it.
sensitivity and specificity of TEE for detection of
LAA thrombi - 92% and 98%
functional assessment of the LAA using Doppler
echocardiography is routinely used.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
23. In SR, the LAA is usually a highly contractile
muscular sac that obliterates its apex during atrial
systole and can be seen by TEE and confirmed
by pulsed and color flow Doppler.
AA velocity and color flow in SR are concordant
with LAA reduction in size, reflecting true
contraction, whereas in AF this normal pattern is
usually replaced by a chaotic one of varying
velocities.
Flow in the appendage -sampling done at the
site where maximal flow velocities are obtained
(usually in the proximal third of the appendage)LAA OCCLUSION FOR STROKE
PREVENTION IN AF
24. LAA flow pattern. A.
sinus rhythm
quadriphasic wave pattern
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
25. B)PWD-tracing of LAA flow in sinus rhythm.
C) PWD-tracing of LAA flow in atrial fibrillation.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
26. normal subjects-, LAA contraction is
quadriphasic with velocities ranging from 50 to
83 cm/s with filling velocities ranging from 46 to
60 cm/s.
Decreased velocities in SR - elevated LA
pressure.
AF- flow signals are highly variable with a
sawtooth pattern or the absence of identifiable
flow waves although they tend to have lower
velocities during ventricular systole (when the
LAA contracts against a closed mitral valve) with
increasing heart rate reducing the peak flow
velocity
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
27. Velocities
highest in SR
intermediate -paroxysmal AF and atrial flutter
lowest -chronic AF.
Velocities <40 cm/s -higher risk of stroke and the
presence of SEC ,
velocities of <20 cm/s -thrombus within the LAA
and a higher incidence of thromboembolic events.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
28. Imaging of the LAA
(1) preprocedural TEE is used to screen suitable
candidates and to define LAA morphology and
dimensions;
(2) periprocedural -guiding delivery and
deployment of the device and for assessing
procedural complications;
(3) postprocedural -surveillance
and monitoring of long-term outcome
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
29. TEE IMAGES OF LAA
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
30. LAA ostium, LAA neck width (orifice width or
‘landing zone’) and LAA depth should be
measured.
The LAA neck width - plane from the LCx
coronary artery to a point 10 mm distal to the
limbus (white arrow) of the left superior
pulmonary vein (LSPV).
risk of undersizing is device embolization
risk of oversizing is compression on the LCx
and/or LSPV, as well as LAA perforation and
device embolisation
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
31. These various LAA configurations can influence
device/size selection and implantation success.
The risk of device dislodgement -highest in horn-
shaped configuration of the LAA.
Choosing a device large enough to cover the
ostium and yet maintain the optimal degree of
oversizing in the ‘landing zone’ to secure
anchorage can be a challenge
Amount of trabeculation of the ‘landing zone’and
the depth of the LAA (especially important if using
the WATCHMAN device) need to be assessed to
ensure that the optimal device is chosen.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
32. Important aspects to assess are the number,
shape and location of the lobes.
large LAA neck width (>26 mm) or complicated
LAA anatomy-preprocedural imaging with CT/MRI
should be considered.
LAA size is dependent on the LA pressure
(‘loading status’) as well as on the presence of
sinus rhythm or AF.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
36. PLAATO device
PLAATO (Percutaneous Left Atrial Appendage
Transcatheter Occlusion) system
first device specifically developed
self-expanding nitinol cage with three anchors on
each strut and was covered with a nonthrombogenic
PTFE membrane.
anchoring barbs provided the stability;
PTFE membrane prevented mobilisation of thrombi
from the LAA and promoted healing.
device diameter ranged between 15 and 32 mm
normally selected 20–40% larger than the diameter of
the LAA ostium.
no longer available for clinical use after withdrawal
from the market in 2006
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
38. Watchman device
approved by FDA in 2015 for nonvalvular AF
patients at risk for stroke without contraindication
to anticoagulation.
Watchman Left Atrial Appendage System for
Embolic Protection in Patients With Atrial
Fibrillation (PROTECT-AF) trial -trial to examine
the efficacy of the Watchman device.
self-expanding nitinol frame covered with a
porous filtering PET (polyethylene terephthalate )
membrane.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
39. stability of the device is secured by fixation barbs
located circumferentially.
PET membrane acts as a filter preventing the
outflow of the thrombi and promotes
endothelialisation.
five different sizes ranging from 21 to 33 mm
selected 10–20% larger than LAA diameter to
ensure stable device positioning.
can be recaptured and withdrawn in case of
suboptimal fixation.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
41. TEE Image LA Angiogram
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
42. ACP Device
lobe and a disk connected by a short, flexible waist, both
the lobe and disk are constructed from a nitinol mesh
covered with a polyester patch.
The lobe is implanted within the neck of the LAA (the so-
called
‘landing zone’), and achieves device stabilization and
retention by means of a number of stabilization wires.
delivery system is 9-13Fr depending on the size of the
device.
lobe size ranges from 16-30 mm and the disk from 20–36
mm;
size of the lobe should be chosen 3 to 5 mm larger than
the diameter of the ‘landing zone’.
not designed to fill the LAA but to seal its ostium by means
of the larger disk.
better choice when challenged with a more complex
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
46. Lariat system
3 components: a balloon catheter, magnet-tipped
guidewires, and an epicardially placed 12-F
suture delivery device.
requires both epicardial and endocardial
approaches to occlude the LAA.
Using a transseptal approach, the LA is entered,
and the
endocardial magnet-tipped guidewire is placed
in the apex of the LAA, over which the balloon
catheter is advanced to the neck of the LAA.
A second magnetic wire is advanced through the
pericardial space to the epicardial surfaceLAA OCCLUSION FOR STROKE
PREVENTION IN AF
47. When the 2 magnetic wires are opposed, a suture can
be guided over the rail formed by the 2 magnet-tipped
guidewires and positioned basal to the balloon
inflated in the neck of the LAA.
Once adequate placement is confirmed with imaging,
the epicardial suture can be secured and the LAA
ligated.
As the Lariat system leaves no hardware inside the
LA after
the LAA is occluded, there is no clear need for
postprocedure anticoagulation.
The Lariat device received 510(k) clearance by the
FDA as a suture for tissue approximation, but not
specifically for LAA exclusion or stroke prevention
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
49. AtriClip
self-closing external rectangular LAA occluder.
4 sizes, from 35 mm to 50 mm, in 5-mm
increments.
2 nitinol springs joined with 2 titanium members
covered with Dacron polyester fabric.
parallel compression planes symmetrically exert a
pressure of 2 to 8 psi over the entire contact area,
effectively forming a surgically implanted clamp
across the base of the LAA.
applied epicardially via a median sternotomy or
video-assisted thorascopic surgical approach .
FDA 510(k) approval of the device
indicated for LAA occlusion under direct
visualization, in conjunction with other open
cardiac surgical procedures..
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
51. NEW LAA OCCLUSION DEVICES
IN
DEVELOPMENT
Sierra Ligation System -epicardial
electrocardiogram-guided LAA capture and
ligation system. =canine models and a feasibility
study is on the way .
Lambre =self-expanding nitinol device with
high success rates in canines.
WaveCrest and Occlutech
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
53. Coherex WaveCrest LAA occlusion
system
latest development in
nitinol frame with retractable coils and anchors to
enable optimal device positioning.
multi-composite membrane including a PTFE
membrane on the LA side of the device, and a
foam substrate on the LA-opposing surface to
minimize residual leaks.
WAVECREST I clinical trial was completed - CE
Mark approval was obtained in September 2013.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
56. Device implantation
general anaesthesia
TEE and fluoroscopic guidance
Antibiotic prophylaxis =prior to the procedure.
Vascular access through a femoral vein
delivery system is introduced by transseptal
puncture using a standard transseptal needle
and sheath.
the puncture site is preferably inferior and
posterior in the fossa
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
57. .
After the puncture,a bolus of unfractionated
heparin to achieve ACT >250 s.
TEE (or intracardiac echocardiography (ICE)) and
contrast angiography of the LAA (right anterior
oblique 30°/cranial 30°) =LAA dimensions(ostium,
neck width, depth)—based on these
measurements, the size of the device is chosen
device is deployed by withdrawing the sheath
over the device (to reduce the risk of perforation).
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
58. .
Once in position, the device stability is confirmed
by a ‘tug test’, and complete sealing is verified by
colour Doppler imaging.
Finally, the device is released from the delivery
cable and possible complications such as
pericardial effusion are ruled out.
To avoid embolism of the Watchman Device,
there are four release criteria that should be
evaluated before release: Position, Anchor, Size
and Seal (PASS).
Position: To confirm that the device is properly
positioned, ensure that the plane of maximum
diameter of the device is at or just distal to the
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
59. LAA OCCLUSION FOR STROKE
PREVENTION IN AF
Anchor: To confirm the device is anchored in
place, withdraw the access sheath/delivery
catheter assembly 1-2 cm from the face of the
device. After injecting a small puff of contrast
gently retract and push the deployment knob to
see the combined movement of the device and
the LAA tissue.
Size: To confirm the correct device size, measure
the plane of the maximum diameter of the device
using TEE in the 4 standard views 0, 45, 90, and
135 degrees, ensuring the threaded insert is
visible. The device size should be 80%-92% of
the nominal diameter.
Seal: Using colour Doppler, ensure that all of the
lobes are distal of the device and are sealed. If
there is a gap visible between the wall of LAA and
the device with more than 3 mm, the device
60. Postprocedural considerations
chest X-ray and TTE before discharge -device
embolisation and pericardial effusion.
After 45 days-control TEE to verify complete
sealing of the LAA and the absence of a
thrombus.
OAC was given for 45 days and patients
discontinued OAC if the 45-day TEE control
showed either complete closure of the LAA or if
the jet width of the residual peridevice flow was
<5 mm.
After stopping OAC therapy, patients were given
DAPT with ASA and clopidogrel until completion
of the 6-month TEE control, after which ASA
monotherapy was continued indefinitely
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
61. WATCHMAN implantation can be safely
performed without OAC transition and that DAPT
prescribed for 6 months followed by ASA alone
ACP device- OAC has been avoided and DAPT
from 1 to 6 months after implantation, followed
by ASA alone.
Incidence of device thrombosis - 4% to 17%.
incidence of thrombus formation is more
frequent in the first few weeks/months and
significantly declines with complete
endothelisation of the occluder surface
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
62. device thrombosis- subcutaneous heparin for 2
weeks followed by TEE, and DAPT therapy is
extended for a longer period.
Risk for thrombus formation on the device -high
platelet count, high stroke risk score and low LV
EF.
After percutaneous LAA exclusion with the Lariat
snare device in which no intracavitary device is
left behind, thrombus formation can occur at the
LAA ostium , so postprocedural antiplatelet
therapy is also indicated for this device
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
64. Complications of percutaneous
LAA
closure
Cardiac perforation
Pericardial effusion with tamponade
Device embolisation
Device thrombosis
Stroke/TIA—thromboembolism, air embolism
Vascular complications
haematoma, bleeding, AV fistula
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
65. Peridevice leaks
(1) severe—multiple jets or free flow;
(2) major—jet width >3 mm;
(3) moderate—jet width of 1–3 mm and
(4) minor—jet width <1 mm.
Major residual leaks -62%,32% and 10% of the
patients after PLAATO, WATCHMAN and ACP
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
66. lower rate of residual leak -ACP implantation
(double-disk structure of the ACP, which may
contribute to a better sealing of the LAA orifice)
presence of residual peridevice leaks has never
been associated with cardioembolic events.
when detecting major residual peridevice leaks,
OAC therapy is continued or restarted for several
weeks /months until the next control TEE in the
hope of a complete closure or jet width <3 mm.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
67. PROTECT AF trial
Only prospective, RCT
707 patients with NVAF -2:1 ratio to either
percutaneous LAA occlusion with the WATCHMAN
device or to warfarin therapy.
paroxysmal,persistent or permanent NVAF were
eligible for enrolment if they had a CHADS2 risk score
≥1
confirmed the non-inferiority of WATCHMAN LAA
occlusion compared with OAC therapy regarding
the
primary efficacy endpoint—a composite of stroke,
systemic
embolism and cardiovascular death (RR=0.62,95% CI
0.35 to 1.25)
The probability of non-inferiority of the intervention
was >99.9%.LAA OCCLUSION FOR STROKE
PREVENTION IN AF
68. 4-year follow-up results from the PROTECT AF trial
were presented
primary efficacy endpoint -40% relative risk reduction
in primary efficacy in the WATCHMAN group.
Cardiovascular death occurred in 1.0% of the device
group vs 2.4% of the warfarin group (p<0.05)
rate of haemorrhagic stroke was 0.2% in the device
group vs 1% in the warfarin group (p<0.05).
long-term follow-up data -additional support
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
69. PREVAIL Study
n=269, WATCHMAN
large multicentre study
ACP device (n=969)
improved procedural safety—complication rates
within
7 days were 4.1%, 4.4% and 4.1%, respectively,
as compared with >7% in the initial PROTECT
AF trial (2009)
lower rates of periprocedural major adverse
events can be ascribed to a better understanding
of the procedure and an operator learning curve
effect.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
71. 5-Year Outcomes
After Left Atrial Appendage
Closure
From the PREVAIL and PROTECT
AF Trials
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
72. • PROTECT AF (WATCHMAN Left Atrial
Appendage System for Embolic Protection in
Patients With Atrial Fibrillation) -Watchman device
was equivalent to warfarin for preventing stroke in
atrial fibrillation, but had a high rate of
complications.
• PREVAIL (Evaluation of the WATCHMAN LAA
Closure Device in Patients with Atrial Fibrillation
Versus Long Term Warfarin Therapy), -
complication rate was low.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF
73. • PREVAIL and PROTECT AF are prospective
randomized clinical trials with patients
randomized 2:1 to LAAC or
warfarin; together, they enrolled 1,114 patients
for 4,343 patient-years.
• These 5-year outcomes of the PREVAIL trial,
combined with the 5-year outcomes of the
PROTECT AF trial-Watchman provides stroke
prevention in NVAF comparable to warfarin,with
additional reductions in major bleeding,
particularly hemorrhagic stroke, and mortality.
LAA OCCLUSION FOR STROKE
PREVENTION IN AF